Related Experiment Video
Updated: Jun 25, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
[Analysis of Test Results of Anti-HCV Reagents in Blood Screening Laboratory]
Xian-Yuan Wang1, Ya-Zi Zhao1, Jing Ren1
1Hebei Blood Center, Shijiazhuang 050071, Hebei Province, China.
Objective:
To analyze the anti-HCV (hepatitis C virus) screening results and confirmatory test results of blood samples in our laboratory, so as to provide a basis for the selection of blood screening strategies.
Methods:
946 anti-HCV ELISA screening non-conforming samples from volunteer blood donors at our center between 2015 and 2023 were randomly selected. Statistical analysis was performed on ELISA results and Western blot (WB) confirmatory test results. The ELISA retest concordance rate, proportion of confirmed positive samples, true positive detection rate and optimal shielding threshold value of four reagents (A, B, C and D) were analyzed.
Results:
The overall retesting concordance rates of the initial screening non-conforming specimens for the four reagents were 69.88%, 27.54%, 84.00% and 69.08%, respectively. Results of WB confirmatory tests showed that the true positive detection rates of the four reagents were 99.49% (391/393), 98.00% (49/50), 93.88% (92/98), and 97.20% (382/393), respectively. The S/CO (sample/cut-off ratio) values of non-conforming samples detected by the four reagents were positively correlated with WB results: the higher the S/CO value, the higher the proportion of confirmed positive samples (r=0.99, 0.95, 0.87, and 0.99, respectively). The receiver operating characteristic (ROC) curves for the detection performance of the four reagents were drawn according to the WB results, and the areas under the curves (AUC) were 0.946, 0.909, 0.934, and 0.967, respectively. The optimal shielding threshold value of S/CO were 5.64, 1.61, 1.58, and 2.42, with corresponding positive predictive values (PPV) of 93.50%, 100%, 100%, and 92.66%, respectively.
Conclusion:
There are certain differences in the detection capabilities of different anti-HCV ELISA screening reagents. Each laboratory can choose different reagent combinations for complementary advantages or set the optimal shielding threshold value of S/CO according to its own needs, so as to improve the accuracy of detection, ensure blood safety, and avoid waste of blood and reagents.
